B-MS and WuXi to collaborate on new testing facility

Published: 8-Mar-2011
Finance Analysis

WuXi will build cGMP facility in Shanghai


WuXi PharmaTech will perform stability studies of Bristol-Myers Squibb small-molecule drug candidates as part of a new partnership announced by the companies this week.

Under the agreement, Wuxi PharmaTech, a Chinese pharmaceutical outsourcing company will build a fully cGMP-compliant 25,000ft2 analytical testing facility in Shanghai and store and test stability samples and perform other services for New York-based Bristol-Myers Squibb. Financial terms were not revealed.

‘This agreement will expand the scope of our relationship with WuXi and enhance the presence of Bristol-Myers Squibb in China,’ said Mark Powell, senior vice president, Non-Clinical Development, Bristol-Myers Squibb.

  • Companies:
  • WuXi AppTec (Shanghai) Co
  • Bristol-Myers Squibb
See more

You may also like

Manufacturing

Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities

Read more
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle

Trending Articles

  1. Medac and chiron develop organ-on chip tech for animal free drug testing The companies aim to develop an animal-free pharmaceutical testing method that utilises organ-on chip technology, and will be used in rheumatoid arthritis drug testing
  2. Siemens Industrial business appoints Finance Director
  3. Agilent Technologies Agilent is a leader in life sciences, diagnostics and applied chemical markets. The company provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling customers to gain the insights they seek. Agilent’s expertise and trusted collaboration give them the highest confidence in our solutions
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    The pros and cons of distribution agreements For life sciences companies seeking to break into overseas markets, distribution agreements are central to success
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Meeting new USP Chapter 41 requirements Balances are the essential means by which all therapeutics are ultimately supplied in safe dosages. Dirk Ahlbrecht, Sartorius Group, looks at how to ensure measurements are both accurate and up to new USP standards

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Manufacturing

Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities

Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Manufacturing

AtkinsRéalis awarded engineering design services contract for API manufacturing facility in Singapore

When completed, the Singapore site will play a critical role in WuXi AppTec’s global network across Asia, Europe and North America, meeting the growing demand from multinational customers and strengthening collaborations with a wide range of partners
Manufacturing

WuXi STA opens oral drug manufacturing facility

The new facility marks a milestone for WuXi STA, further extending its drug product capacity and capabilities to meet the growing demand for HP drug candidate development
Manufacturing

WuXi STA breaks ground for new pharmaceutical manufacturing facility in Middletown, Delaware

WuXi STA, a leading contract research, development and manufacturing organisation (CRDMO), is pleased to announce the groundbreaking for its new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware
Manufacturing

WuXi STA opens a new large-scale continuous manufacturing plant

Company continues to enhance the flow chemistry platform for more sustainable production
Manufacturing

WuXi STA opens new large-scale oligonucleotide and peptide manufacturing facility

Site enhances new modality CRDMO platform capacity for customers
Finance

WuXi STA to become preferred CDMO for Coherent Biopharma

PDC drugs have broad applications, but development faces many technical challenges
Subscribe now